New cell therapy for CD7-positive T-cell leukemia in children and teens
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new type of cell therapy for children and teens with a tough-to-treat form of acute T-cell leukemia that is CD7-positive. The goal is to see if it is safe and can help when other treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 2 and 18 years old.
- Your leukemia must have come back after treatment or not responded to standard treatments.
- The leukemia cells must have a marker called CD7 on them, which we will check.
- You must have tried at least one other treatment and still have leukemia cells in your bone marrow.
- You need to be generally healthy enough for this study, with good heart, lung, and liver function.
- If you are of childbearing age, you must agree to use effective birth control for a year after the cell infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests an experimental immunotherapy (PA3-17) designed to target and kill cancer cells that carry the CD7 marker in children and teens with T-cell leukemia or lymphoma that has returned or is hard to treat. It aims to see if the treatment is safe and effective at the best dose.
This trial tests a new treatment called CD7 CAR-T for children with a high-risk type of blood cancer (T-cell leukemia or lymphoma). It aims to reduce the chance of the cancer coming back after initial treatment.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests an experimental treatment called BG1805 for children with acute myeloid leukemia (AML) that has returned or not responded to standard therapy. BG1805 is a type of cell therapy (like CAR-T) that targets the CLL-1 marker on leukemia cells, potentially helping the body fight the cancer.
This trial tests a new treatment using the patient's own immune cells, modified to find and attack leukemia cells that remain after initial chemotherapy. It's for children with B-cell acute lymphoblastic leukemia who still have tiny amounts of cancer cells detectable after standard treatment.
Hear when a new T-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.